Endonovo Therapeutics, Inc.
ENDV· OTC
ENDVEndonovo Therapeutics, Inc.
Quarterly figures for Endonovo Therapeutics, Inc., with source filings when available.
48 quarters. Mar 31, 2011 to Sep 30, 2023. USD.
Endonovo Therapeutics, Inc. has filed its 10-Q within 49 to 90 days of period end across its last 8 quarters. The 10-K runs 96 to 125 days.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2023 | |||||||||
| Q3 2023 | Sep 30, 2023 | — | Dec 29, 2023 | 90 d | 10-Q | $1.52K | −86.1% | $0.00 | |
| Q2 2023 | Jun 30, 2023 | — | Aug 21, 2023 | 52 d | 10-Q | $45.20K | +6,853.8% | -$0.01 | |
| Q1 2023 | Mar 31, 2023 | — | May 22, 2023 | 52 d | 10-Q | $87.54K | +3,736.1% | $0.00 | |
| FY 2022 | |||||||||
| Q4 2022derived | Dec 31, 2022 | — | Apr 17, 2023 | 107 d | 10-K | $121.46K | +38,337.7% | — | |
| Q3 2022 | Sep 30, 2022 | — | Nov 21, 2022 | ||||||
| FY 2021 | |||||||||
| Q4 2021derived | Dec 31, 2021 | — | Apr 14, 2022 | 104 d | 10-K | $316.00 | −97.3% | — | |
| Q3 2021 | Sep 30, 2021 | — | Nov 19, 2021 | ||||||
| FY 2020 | |||||||||
| Q4 2020derived | Dec 31, 2020 | — | Apr 13, 2021 | 103 d | 10-K | $11.50K | −92.3% | — | |
| Q3 2020 | Sep 30, 2020 | — | Nov 19, 2020 | ||||||
| FY 2019 | |||||||||
| Q4 2019derived | Dec 31, 2019 | — | May 4, 2020 | 125 d | 10-K | $148.44K | +252.3% | — | |
| Q3 2019 | Sep 30, 2019 | — | Nov 19, 2019 | ||||||
| FY 2018 | |||||||||
| Q4 2018derived | Dec 31, 2018 | — | Apr 15, 2019 | 105 d | 10-K | $42.13K | — | — | |
| Q3 2018 | Sep 30, 2018 | — | Nov 13, 2018 | ||||||
| FY 2017 | |||||||||
| Q4 2017derived | Dec 31, 2017 | — | Apr 6, 2018 | 96 d | 10-K | — | — | — | |
| Q3 2017 | Sep 30, 2017 | — | Nov 7, 2017 | 38 d | 10-Q | ||||
| FY 2016 | |||||||||
| Q4 2016derived | Dec 31, 2016 | — | Apr 17, 2017 | 107 d | 10-K | — | — | — | |
| Q3 2016 | Sep 30, 2016 | — | Nov 14, 2016 | 45 d | 10-Q | ||||
| FY 2015 | |||||||||
| Q4 2015derived | Dec 31, 2015 | — | Apr 5, 2016 | 96 d | 10-K | $0.00 | — | — | |
| Q3 2015 | Sep 30, 2015 | — | Nov 23, 2015 | ||||||
| FY 2014 | |||||||||
| Q4 2014derived | Dec 31, 2014 | — | Apr 3, 2015 | 93 d | 10-K | — | — | — | |
| Q3 2014 | Sep 30, 2014 | — | Nov 14, 2014 | 45 d | 10-Q | ||||
| FY 2013 | |||||||||
| Q4 2013derived | Dec 31, 2013 | — | Apr 15, 2014 | 105 d | 10-K | $22.90K | +67.7% | — | |
| Q3 2013 | Sep 30, 2013 | — | Dec 18, 2013 | ||||||
| FY 2012 | |||||||||
| Q4 2012derived | Dec 31, 2012 | — | Apr 16, 2013 | 106 d | 10-K | $13.66K | — | — | |
| Q3 2012 | Sep 30, 2012 | — | Nov 29, 2012 | ||||||
| FY 2011 | |||||||||
| Q1 2011 | Mar 31, 2011 | — | — | — | — | $0.00 | — | $0.00 | |
| 52 d |
| 10-Q |
| $10.96K |
| +40.7% |
| $0.00 |
| Q2 2022 | Jun 30, 2022 | — | Aug 22, 2022 | 53 d | 10-Q | $650.00 | −97.9% | -$0.02 |
|---|
| Q1 2022 | Mar 31, 2022 | — | May 19, 2022 | 49 d | 10-Q | $2.28K | −93.4% | -$0.03 |
|---|
| 50 d |
| 10-Q |
| $7.79K |
| −80.5% |
| -$0.02 |
| Q2 2021 | Jun 30, 2021 | — | Aug 23, 2021 | 54 d | 10-Q | $30.28K | −32.1% | -$0.02 |
|---|
| Q1 2021 | Mar 31, 2021 | — | May 24, 2021 | 54 d | 10-Q | $34.72K | −50.2% | -$0.06 |
|---|
| 50 d |
| 10-Q |
| $39.98K |
| −26.0% |
| -$0.07 |
| Q2 2020 | Jun 30, 2020 | — | Aug 19, 2020 | 50 d | 10-Q | $44.63K | −28.9% | -$0.17 |
|---|
| Q1 2020 | Mar 31, 2020 | — | Jun 12, 2020 | 73 d | 10-Q | $69.69K | +55.0% | -$0.14 |
|---|
| 50 d |
| 10-Q |
| $54.04K |
| +153.6% |
| -$1.81 |
| Q2 2019 | Jun 30, 2019 | — | Aug 13, 2019 | 44 d | 10-Q | $62.73K | +388.0% | -$13.57 |
|---|
| Q1 2019 | Mar 31, 2019 | — | May 9, 2019 | 39 d | 10-Q | $44.95K | +544.8% | -$4.99 |
|---|
| 44 d |
| 10-Q |
| $21.31K |
| — |
| -$0.02 |
| Q2 2018 | Jun 30, 2018 | — | Aug 13, 2018 | 44 d | 10-Q | $12.85K | — | $0.00 |
|---|
| Q1 2018 | Mar 31, 2018 | — | May 18, 2018 | 48 d | 10-Q | $6.97K | — | $0.00 |
|---|
| — |
| — |
| -$0.03 |
| Q2 2017 | Jun 30, 2017 | — | Aug 10, 2017 | 41 d | 10-Q | — | — | $0.01 |
|---|
| Q1 2017 | Mar 31, 2017 | — | May 12, 2017 | 42 d | 10-Q | — | — | -$0.05 |
|---|
| — |
| — |
| -$0.02 |
| Q2 2016 | Jun 30, 2016 | — | Aug 12, 2016 | 43 d | 10-Q | — | — | -$0.01 |
|---|
| Q1 2016 | Mar 31, 2016 | — | May 20, 2016 | 50 d | 10-Q | $0.00 | −100.0% | -$0.01 |
|---|
| 54 d |
| 10-Q |
| — |
| — |
| -$0.01 |
| Q2 2015 | Jun 30, 2015 | — | Aug 19, 2015 | 50 d | 10-Q | $1.92K | −88.3% | -$0.01 |
|---|
| Q1 2015 | Mar 31, 2015 | — | May 19, 2015 | 49 d | 10-Q | $2.75K | −84.5% | -$0.01 |
|---|
| $20.64K |
| — |
| $0.00 |
| Q2 2014 | Jun 30, 2014 | — | Aug 19, 2014 | 50 d | 10-Q | $16.42K | — | $0.26 |
|---|
| Q1 2014 | Mar 31, 2014 | — | May 15, 2014 | 45 d | 10-Q | $17.76K | — | -$0.01 |
|---|
| 79 d |
| 10-Q |
| $0.00 |
| −100.0% |
| -$0.01 |
| Q2 2013 | Jun 30, 2013 | — | Aug 19, 2013 | 50 d | 10-Q | $0.00 | −100.0% | -$0.01 |
|---|
| Q1 2013 | Mar 31, 2013 | — | May 20, 2013 | 50 d | 10-Q | $0.00 | −100.0% | -$0.02 |
|---|
| 60 d |
| 10-Q |
| $7.16K |
| — |
| -$0.01 |
| Q2 2012 | Jun 30, 2012 | — | Aug 20, 2012 | 51 d | 10-Q | $8.09K | — | -$0.01 |
|---|
| Q1 2012 | Mar 31, 2012 | — | May 21, 2012 | 51 d | 10-Q | $1.67K | — | -$0.01 |
|---|
